By: IPP Bureau
Last updated : June 03, 2026 6:32 am
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
Intracin Pharmaceutical, a specialized veterinary pharmaceutical manufacturing company, has received approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA), enabling the company to supply veterinary pharmaceutical products to the Australian market.
The approval, granted on May 21, 2026, marks a significant regulatory milestone for the company and underscores its commitment to maintaining high standards of quality, compliance, and manufacturing excellence in animal healthcare.
Brijesh Desai, Director, Intracin Pharmaceutical, said, “The APVMA approval is a major milestone for Intracin Pharma and validates our commitment to providing high-quality veterinary healthcare solutions.”
“As a company dedicated exclusively to veterinary formulations, this approval strengthens our global regulatory credentials and opens new opportunities to serve the Australian animal health sector,” said Desai.
He added, “We remain committed to supporting veterinarians, livestock producers, and animal owners with safe, effective, and quality veterinary medicines.”
The APVMA approval enables Intracin Pharmaceutical to expand its presence in one of the world's highly regulated veterinary healthcare markets. The company manufactures a broad portfolio of veterinary formulations and currently serves customers across multiple international markets.